'What is the Clinical Value of Day 7 Blastocysts?' New Study Makes Case for Culturing Embryos Up to Seven Days Post-Insemination for Selected Patients
Retrieved on:
Tuesday, May 3, 2022
Child, Genetic testing, LBS, Culture, Twitter, Failure, IVF, Health, Pregnancy, Research, Data collection, Patient, Infertility, TEL, Live birth, Angelo Cimadomo, Artificial intelligence, International Institute of Rehabilitation Sciences and Research, Observational study, LinkedIn, Rienzi, CEO, Technology, Portrait, Generalife, Entrepreneurship, Bias, Human Reproduction (journal), Medical device, Mineral oil, Silviculture, Science
TEL AVIV, Israel, May 3, 2022 /PRNewswire/ -- Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the results of a new study published in Human Reproduction, "How slow is too slow? A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence," finding that ending embryo culture at 144 hours (six days) post-insemination (h.p.i.) would involve 7.3 percent and 4.4 percent relative reductions in the number of patients obtaining euploid blastocysts and live birth(s) (LBs), respectively.
Key Points:
- A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence," finding that ending embryo culture at 144hours (six days) post-insemination (h.p.i.)
- would involve 7.3 percent and 4.4 percent relative reductions in the number of patients obtaining euploid blastocysts and live birth(s) (LBs), respectively.
- "Fairtility's AI-powered tool can help IVF professionals make the most of time-lapse data through standardized and reproducible evaluations.
- Here it made objective the clinical value of Day 7 embryos, opening up possibilities for couples struggling to get pregnant and to clinics contemplating a 6-to-7-day culture."